Marrone Bio Innovations, Inc. (NASDAQ:MBII) marched up 100% compared to a 52-week low price of $0.85. The shares were last seen trading 8.28% higher, taking the closing price at $1.7 on 03/13/2018. At recent session, the prices were hovering between $1.55 and $1.75. This company shares are 30.59% off its target price of $2.22 and the current market capitalization stands at $43.33M. The recent change has given its price a 42.63% lead over SMA 50 and -26.09% deficit over its 52-week high. The stock witnessed 37.1% gains, 77.06% gains and 47.83% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found MBII’s volatility during a week at 18.17% and during a month it has been found around 9.44%.Marrone Bio Innovations, Inc. (MBII) Top Holders
Institutional investors currently hold around $18 million or 39% in MBII stock. Look at its top three institutional owners. Waddell & Reed Financial Inc owns $7.4 million in Marrone Bio Innovations, Inc., which represents roughly 17.08% of the company’s market cap and approximately 41.12% of the institutional ownership. Similar statistics are true for the second largest owner, Ardsley Advisory Partners, which owns 3,681,580 shares of the stock are valued at $5.78 million. The third largest holder is Primecap Management Co/Ca/, which currently holds $4.12 million worth of this stock and that ownership represents nearly 9.51% of its market capitalization.
At the end of 12/31/2017 reporting period, 3 institutional holders increased their position in Marrone Bio Innovations, Inc. (NASDAQ:MBII) by some 99,149 shares, 8 decreased positions by 141,930 and 11 held positions by 11,501,513. That puts total institutional holdings at 11,742,592 shares, according to SEC filings. The stock grabbed 1 new institutional investments totaling 11,500 shares while 5 institutional investors sold out their entire positions totaling 103,105 shares.Marrone Bio Innovations, Inc. (NASDAQ:MBII) Insider Trades
Multiple company employees have indulged in significant insider trading. Marrone Bio Innovations, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that 10% Owner Van Herk Investments B.V. has sold 5,000 shares of Marrone Bio Innovations, Inc. (MBII) in trading session dated Feb. 12, 2018. These shares are worth $6,150 and were traded at $1.23 each. The SEC filing shows that Ardsley Advisory Partners performed a purchase of 6,666,667 shares. The added these shares by way of transaction on Feb. 05, 2018. The company’s shares were assimilated at $0.75 per share worth to an investment of some $5,000,000 on account of Ardsley Advisory Partners.
10% Owner, Ardsley Advisory Partners, sold 1,189,700 common shares of Marrone Bio Innovations, Inc. (MBII) in the open market. In a transaction dated Apr. 28, 2017, the shares were put up for sale at an average price of $1.68, raking in a sum of $1,998,696. After this sale, 2,491,880 common shares of MBII are directly owned by the insider, with total stake valued at $4,236,196.
In the transaction dated Apr. 25, 2017, the great number of shares acquired came courtesy the 10% Owner; Ardsley Advisory Partners added a total of 50,000 shares at an average price of $1.72, amounting to approximately $86,000. The insider now directly owns 3,681,580 shares worth $6,258,686.Marrone Bio Innovations, Inc. (MBII) Analyst Guide
Several analysts have released their opinion on Marrone Bio Innovations, Inc. (NASDAQ:MBII), with 1 analysts believing it is a strong buy. Whereas 1 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2 average brokerage recommendation.